Wednesday, March 1, 2017
13:00-14:30 - Auditorium I
Session Supported by Roche
HPV Primary Screening and Beyond: Improving Patient Outcomes Around the World
Thursday, March 2, 2017
07:30-08:30 Meeting Room 1.43 Session Supported by
Breakfast Satellite (Breakfast bags will be provided)
Moderators:
Philip Castle, USA
Anna-Lise Williamson, South Africa
Symposium:
Utility of Xpert® HPV for Cervical Cancer Screening of HIV-Positive Women
Louise Kuhn, USA
Practical Considerations Around Using Xpert® HPV in Low Income Countries,
Focusing on Malawi
Heather Cubie, UK
HPV Diagnostic Testing Under the New Australian National Cervical
Screening Program, Including Self-Collection
David Hawkes, Australia
Point-of-Care HPV Testing for Cervical Screening in High-Buden,
Low-income Settings
Andrew Vallely, Australia
Dr. Castle, Dr. Vallely, and Dr. Hawkes are independent participants in this event who have
not, nor will receive any form form of compensation from Cepheid.
13:30-15:00 - Auditorium II
Session Supported by Hologic
Preventing HPV related cancers globally: Specific tools and strategies
Chairperson: Hennie Botha, South Africa
- Introduction & cervical cancer screening in Africa
Hennie Botha, Stellenbosch University Cape Town, South Africa
- The use of HPV oncogenic E6/E7 mRNA for cancer screening in HIV infected populations and beyond
John-Paul Bogers, University of Antwerp, Antwerp, Belgium
- Performance of HPV tests in screening young vaccinated women: Results of the SHEVA study
Ramya Bhatia, University of Edinburgh, Edinburgh, UK
-Searching for the right combinations of vaccination and screening for cervical cancer prevention: The HPV FASTER project
Xavier Bosch, Institut Catala d'Oncologia, Barcelona, Spain
-Discussion and Questions
Friday, march 3, 2017
07:50-09:20 - Auditorium II
Session supported by GSK/Aspen
Spotlight on Cervical Cancer prevention: HPV vaccination in South Africa and beyond
Welcome and Introduction
Dr. Olakunle Oladehin
Expert Panel Discussion
Dr. Olakunle Oladhehin
Prof. Lynette Denny
Prof. Hennie Botha
Dr. Valérie Berlaimont
Dr. Martin Ryser
Concluding Remarks and QA
Dr. Olakunle Oladehin
12:40-14:10 - Ballroom West
Supported through an independent educational grant from Merck & Co., Inc., Kenilworth, NJ, USA
The Story of HPV: Yesterday, Today, and Tomorrow
Activity Overview: Healthcare providers in multiple disciplines worldwide are in unique positions to leave a powerful legacy of cancer prevention in the hundreds of thousands of children and young adults they care for. In this symposium, an international panel of experts will weave the story of HPV prevention – past, present, and future – with a focus on what we've learned, what works, and lessons on advocacy from clinic to national health programs.
Chair: Kenneth A. Alexander, MD, PhD (United States)
Panel: Phionah L. Atuhebwe, MBChB, MPH (Uganda), Stephen Goldstone, MD (United States), Margaret Stanley, MB, PhD (United Kingdom)
Welcome and Introduction
Kenneth A. Alexander
Historical Perspective: From Hypothesis to Discovery
Margaret Stanley
Recent Developments
Kenneth A. Alexander
HPV in Males: What Have We Learned?
Stephen Goldstone
Implementation Progress & Woes
Kenneth A. Alexander
The Imbalance of Disease: HPV in the Developing World
Phionah L. Atuhebwe
Vaccine Safety Scares: Fact or Fiction?
Margaret Stanley
Overcoming Barriers and Challenges
Kenneth A. Alexander
Questions & Answers
Panel
Closing Remarks
Kenneth A. Alexander
To pre-register for the symposium please click here
17:30-19:00 - Ballroom West
Session supported by BD
Cervical Cancer Screening and HPV genotyping:
New Results from the BD Onclarity US Registration trial and Danish Self Sampling study
Symposium Chair
Dr. Judith Whittaker
Balancing Prevalence vs. Risk for CIN3+ by HPV Genotype: Perspectives from the BD Onclarity HPV Clinical Trial
Mark H Stoler
Performance of the BD Onclarity HPV Assay in Women 25+ Years Enrolled in the US Registration Trial
Thomas C. Wright
HPV Self-sampling for Non-attenders in Denmark: From Pilot to 2017 Implementation
Jesper Bonde
